Liu Jinyan, Ewald Bonnie A, Lynch Diana M, Denholtz Matthew, Abbink Peter, Lemckert Angelique A C, Carville Angela, Mansfield Keith G, Havenga Menzo J, Goudsmit Jaap, Barouch Dan H
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
J Virol. 2008 May;82(10):4844-52. doi: 10.1128/JVI.02616-07. Epub 2008 Mar 12.
Recombinant adenovirus serotype 5 (rAd5) vaccine vectors for human immunodeficiency virus type 1 (HIV-1) and other pathogens have been shown to elicit antigen-specific cellular immune responses. Rare serotype rAd vectors have also been constructed to circumvent preexisting anti-Ad5 immunity and to facilitate the development of novel heterologous rAd prime-boost regimens. Here we show that rAd5, rAd26, and rAd48 vectors elicit qualitatively distinct phenotypes of cellular immune responses in rhesus monkeys and can be combined as potent heterologous prime-boost vaccine regimens. While rAd5-Gag induced primarily gamma interferon-positive (IFN-gamma(+)) and IFN-gamma(+)/tumor necrosis factor alpha(+) (TNF-alpha(+)) T-lymphocyte responses, rAd26-Gag and rAd48-Gag induced higher proportions of interleukin-2(+) (IL-2(+)) and polyfunctional IFN-gamma(+)/TNF-alpha(+)/IL-2(+) T-lymphocyte responses. Priming with the rare serotype rAd vectors proved remarkably effective for subsequent boosting with rAd5 vectors. These data demonstrate that the rare serotype rAd vectors elicited T-lymphocyte responses that were phenotypically distinct from those elicited by rAd5 vectors and suggest the functional relevance of polyfunctional CD8(+) and CD4(+) T-lymphocyte responses. Moreover, qualitative differences in cellular immune responses may prove critical in determining the overall potency of heterologous rAd prime-boost regimens.
用于1型人类免疫缺陷病毒(HIV-1)及其他病原体的重组5型腺病毒(rAd5)疫苗载体已被证明可引发抗原特异性细胞免疫反应。还构建了罕见血清型的rAd载体,以规避预先存在的抗Ad5免疫,并促进新型异源rAd初免-加强方案的开发。在此,我们表明rAd5、rAd26和rAd48载体在恒河猴中引发了性质不同的细胞免疫反应表型,并且可以组合成有效的异源初免-加强疫苗方案。虽然rAd5-Gag主要诱导γ干扰素阳性(IFN-γ(+))和IFN-γ(+)/肿瘤坏死因子α(+)(TNF-α(+))T淋巴细胞反应,但rAd26-Gag和rAd48-Gag诱导出更高比例的白细胞介素-2(+)(IL-2(+))和多功能IFN-γ(+)/TNF-α(+)/IL-2(+) T淋巴细胞反应。用罕见血清型rAd载体进行初免被证明对随后用rAd5载体加强免疫非常有效。这些数据表明,罕见血清型rAd载体引发的T淋巴细胞反应在表型上与rAd5载体引发的反应不同,并提示了多功能CD8(+)和CD4(+) T淋巴细胞反应的功能相关性。此外,细胞免疫反应的定性差异可能在决定异源rAd初免-加强方案的总体效力方面至关重要。